Qiming Venture Partners Welcomes Apollomics' Successful IPO on Nasdaq

Rhea-AI Summary

On March 30, 2023, Apollomics Inc. successfully listed on Nasdaq under the symbol APLM through a SPAC merger with Maxpro Capital Acquisition Corp. The IPO opened at $18.60, a 172% increase from the issue price of $10.00, resulting in a market cap of $2.6 billion. Founded in 2015, Apollomics focuses on developing innovative oncology therapies, with six of its nine drug candidates currently in clinical stages. The company has achieved significant milestones, including Orphan Drug Designation for vebreltinib (APL-101) for non-small cell lung cancer. It also has Breakthrough Therapy Designation for uproleselan (APL-106) in acute myeloid leukemia, with Phase 3 patient recruitment expected to complete this year.

Positive

• IPO achieved a market cap of $2.6 billion.
• Stock opened at $18.60, a 172% increase from the issue price.
• Six out of nine oncology drug candidates are in clinical development.
• Vebreltinib (APL-101) received Orphan Drug Designation from the US FDA.
• Uproleselan (APL-106) has Breakthrough Therapy Designation in the US and China.

Negative

• None.

SHANGHAI, March 31, 2023 /PRNewswire/ -- On March 30, 2023, Apollomics Inc. ("Apollomics"), an innovative biopharmaceutical company and portfolio company of Qiming Venture Partners, listed on Nasdaq through a SPAC merger with Maxpro Capital Acquisition Corp. The combined company is now traded under the symbol APLM with an issue price of $10.00/share and an opening price of $18.60/share, up by 172% at closing price on the first day, representing a market cap of $2.6 billion.

Qiming Venture Partners is one of the earliest investors of Apollomics, accompanying the company growth since its Pre-A round. Apollomics' IPO marks Qiming's 5^th IPO since 2023.

Founded in 2015, Apollomics is committed to the discovery and development of mono- and combination-oncology therapies for cancer treatment. The company has built a pipeline includes nine novel oncology drug candidates, six of which are currently in clinical stage of development. By using targeted therapy, immuno-oncology agents, and other innovative approaches, Apollomics' novel drug candidates have the potential to address a range of cancers, including lung cancer, brain cancer, acute myeloid leukemia, and other solid tumors.

The company has achieved breakthroughs in recent years. In 2022, the US FDA has granted Orphan Drug Designation to vebreltinib (APL-101), a highly specific cMet inhibitor, in non-small cell lung cancer and other solid tumors with cMet dysregulation. Apollomics expects results from its global Phase 2 multi-cohort clinical trial this year, which may support its first new drug application with the US FDA while generating clinical data on other indications.

Apollomics is also developing uproleselan (APL-106), an E-selectin inhibitor, in China as an adjunct to chemotherapy to enhance its anti-cancer effects for adult patients with relapsed or refractory acute myeloid leukemia. Uproleselan (APL-106) has received Breakthrough Therapy Designation by the US FDA and the China National Medical Products Administration (NMPA). And the company expects to complete patient recruitment of its Phase 3 study in China this year. 

"Becoming a public company represents a major milestone in our journey to provide solutions for patients with difficult-to-treat cancers worldwide," said Dr. Guo-Liang Yu, Ph.D., Chairman and Chief Executive Officer of Apollomics. "The funds now available to us are expected to facilitate development of our oncology pipeline and further our mission to provide patients with effective therapies and hope." 

"Apollomics team has been working diligently to develop innovative cancer therapies and has built an extensive pipeline. We believe the successful IPO debut today will help the company further expand clinical trials and invest in research and development, continuously making groundbreaking strides in the field of cancer treatment. The core value of innovative drugs is to address unmet clinical needs, and Qiming will continue to focus on this area, benefiting more patients worldwide." said Nisa Leung, Managing Partner of Qiming Venture Partners.

About Qiming Venture Partners

Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston and the San Francisco Bay Area.

Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.4 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.

Since our debut, we have backed over 480 fast-growing and innovative companies. Over 180 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange or Shenzhen Stock Exchange, or through M&A or by other means. There are also over 70 portfolio companies that have achieved unicorn status.

Many of our portfolio companies are today's most influential firms in their respective sectors, including Xiaomi, Meituan, Bilibili, Zhihu, Roborock, Gan & Lee Pharmaceuticals, Tigermed, Zai Lab, CanSino Biologics, Schrödinger, APT Medical, New Horizon Health, Venus MedTech, Sanyou Medical, AmoyDx, Berry Genomics, SinocellTech, Yuanxin Technology, Caidya, Belief BioMed, WeRide, Biren Technology and UBTech among many others.

View original content:https://www.prnewswire.com/news-releases/qiming-venture-partners-welcomes-apollomics-successful-ipo-on-nasdaq-301786963.html

SOURCE Qiming Venture Partners

FAQ

What was Apollomics' opening stock price on Nasdaq?

Apollomics opened at $18.60 on Nasdaq.

What is the stock symbol for Apollomics?

The stock symbol for Apollomics is APLM.

How much was Apollomics' IPO issue price?

The IPO issue price for Apollomics was $10.00 per share.

What is the current market cap of Apollomics after its IPO?

The market cap of Apollomics is $2.6 billion.

What oncology therapies is Apollomics developing?

Apollomics is developing therapies for various cancers, including lung cancer and acute myeloid leukemia.